ClinicalTrials.gg
CompletedNCT01317615Updated Mar 30, 2016Results posted

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

A Phase 4 interventional study of RAD001 and Paclitaxel in Carcinoma, Large Cell and Neuroendocrine Tumors, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multi-centric, open-label study evaluating the efficacy and safety of RAD001 in patients with advanced (stage IV) Lung Cancer (Large Cell) with neuroendocrine differentiation treated with a combination of RAD001 with paclitaxel and carboplatin.

02

Conditions studied

  • Carcinoma, Large Cell
  • Neuroendocrine Tumors

Keywords

  • Large cell carcinoma,
  • Lung cancer,
  • Neuroendocrine Tumors,
  • RAD001
03

In context

Carcinoma, Large Cell

20 studies on the registry are indexed under Carcinoma, Large Cell; 1 is open to participants now.

This study's enrollment of 49 is below the median of 74 across 17 interventional studies indexed under Carcinoma, Large Cell.

Browse Carcinoma, Large Cell studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who give a written obtained according to local guidelines
  2. confirmed diagnosis of stage IV lung cancer of LC-NEC type according to WHO classification:

    1. Histolocial analysis of newly diagnosed disease must not be older than 8 weeks from signed consent
    2. Relapse must be confirmed by histology
    3. Neuroendocrine differentiation
  3. World Health organisation (WHO) performance status grade ≤ 1
  4. Adequate bone marrow function
  5. Adequate liver function
  6. Adequate renal function

Exclusion criteria

Exclusion Criteria:

  1. History or clinical evidence of central nervous system (CNS) .
  2. Presence of SCLC cells
  3. Patients who have a history of another primary ≤ 3 years, with the exception of inactive basal or squamous cell carcinoma of the skin or cervical cancer in situ, early stages of breast cancer (LCIS and DCIS) and prostate cancer (stage T1a)
  4. prior chemotherapy for the treatment of advanced lung cancer and/or not having recovered from the side effects of any other therapy ( treatment for earlier stages I-III is allowed if finished at least one year before study entry)
  5. Patients who have received any drug ≤ 28 days before starting study treatment or who have not recovered from side effects of such therapy
  6. Patients who have not recovered from the side effects of any major surgery or patients that may require major surgery during the course of the study
  7. Patients who have received prior therapy with RAD001 or other mTOR inhibitors
  8. Having any severe and/or uncontrolled medical conditions
  9. Women who are pregnant or breast feeding

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    RAD001 plus paclitaxel/carboplatin

    Participants received RAD001 5 mg orally once daily in combination with carboplatin and paclitaxel for a maximum 4 cycles or until discontinuation.

    Drug: RAD001 · Drug: Paclitaxel · Drug: Carboplatin

Interventions

  • DrugRAD001

    Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.

    Also known as: Everolimus

  • Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.

  • Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Progression-free

    Tumors were assessed according to Response Evaluation Criteria in Solid tumors (RECIST) to determine progression-free status. Complete response (CR): disappearance of all lesions (i.e. all evidence of disease, not just the target lesions) determined by 2 observations not less than 4 weeks apart; Partial response (PR): \> 30% decrease in the sum of longest diameters of target lesions compared to baseline, with response or stable disease observed in non-target lesions, and no new lesions; Stable disease (SD): neither sufficient shrinkage to qualify for response or sufficient increase to qualify for progressive disease in target lesions, with response or stable disease observed in non-target lesions, and no new lesions; Progressive disease (PD): \> 20% increase in the sum of longest diameters of target lesions compared to smallest sum longest diameter recorded. In addition, the sum must also demonstrate an absolute increase of at least 5mm.

    Time frame: 3 months

Secondary outcomes

  1. Percentage of Participants Progression-free

    Tumors were assessed according to Response Evaluation Criteria in Solid tumors (RECIST) to determine progression-free status. Complete response (CR) is disappearance of all lesions (i.e. all evidence of disease, not just the target lesions) determined by 2 observations not less than 4 weeks apart; Partial response (PR) is \> 30% decrease in the sum of longest diameters of target lesions compared to baseline, with response or stable disease observed in non-target lesions, and no new lesions; Stable disease (SD) is neither sufficient shrinkage to qualify for response or sufficient increase to qualify for progressive disease in target lesions, with response or stable disease observed in non-target lesions, and no new lesions; and Progressive disease (PD is: \> 20% increase in the sum of longest diameters of target lesions compared to smallest sum longest diameter recorded. In addition, the sum must also demonstrate an absolute increase of at least 5mm.

    Time frame: 6 months

  2. Percentage of Participants With Overall Response Rate (ORR)

    ORR was defined as is the proportion of participants with a best overall response of CR or PR. CR is disappearance of all lesions (i.e. all evidence of disease, not just the target lesions) determined by 2 observations not less than 4 weeks apart; Partial response. PR is \> 30% decrease in the sum of longest diameters of target lesions compared to baseline, with response or stable disease observed in non-target lesions, and no new lesions.

    Time frame: 3 months

  3. Percentage of Participants With Disease Control Rate (DCR)

    DCR was defined as is the percentage of participants with a best overall response of CR or PR or SD. Complete response (CR) is disappearance of all lesions (i.e. all evidence of disease, not just the target lesions) determined by 2 observations not less than 4 weeks apart; Partial response (PR) is \> 30% decrease in the sum of longest diameters of target lesions compared to baseline, with response or stable disease observed in non-target lesions, and no new lesions; Stable disease (SD) is neither sufficient shrinkage to qualify for response or sufficient increase to qualify for progressive disease in target lesions, with response or stable disease observed in non-target lesions, and no new lesions; and Progressive disease (PD is: \> 20% increase in the sum of longest diameters of target lesions compared to smallest sum longest diameter recorded. In addition, the sum must also demonstrate an absolute increase of at least 5mm.

    Time frame: 3 months

  4. Progression Free Survival (PFS)

    PFS was defined as the time from the date of start of treatment to date of event defined as the first documented progression or death due to any cause.

    Time frame: 6 months

  5. Overall Survival (OS)

    OS was defined as the time from date of start of treatment to date of death due to any cause.

    Time frame: 12 months

07

Results

Posted Mar 30, 2016

Participant flow

This was an open-label, single arm study.

Participant flow — Overall Study
MilestoneRAD001 Plus Paclitaxel/Carboplatin
Started49
Completed0
Not completed49
Withdrew: Disease progression25
Withdrew: New cancer therapy5
Withdrew: Death6
Withdrew: Withdrawal by subject5
Withdrew: Abnormal laboratory value(s)1
Withdrew: Adverse event7

Outcome measures

PrimaryPercentage of Participants Progression-free

Tumors were assessed according to Response Evaluation Criteria in Solid tumors (RECIST) to determine progression-free status. Complete response (CR): disappearance of all lesions (i.e. all evidence of disease, not just the target lesions) determined by 2 observations not less than 4 weeks apart; Partial response (PR): \> 30% decrease in the sum of longest diameters of target lesions compared to baseline, with response or stable disease observed in non-target lesions, and no new lesions; Stable disease (SD): neither sufficient shrinkage to qualify for response or sufficient increase to qualify for progressive disease in target lesions, with response or stable disease observed in non-target lesions, and no new lesions; Progressive disease (PD): \> 20% increase in the sum of longest diameters of target lesions compared to smallest sum longest diameter recorded. In addition, the sum must also demonstrate an absolute increase of at least 5mm.

Time frame:
3 months
Reported as:
Number · Percentage of participants
Percentage of Participants Progression-free
Percentage of participantsRAD001 Plus Paclitaxel/Carboplatin
Percentage of Participants Progression-free49.0
SecondaryPercentage of Participants Progression-free

Tumors were assessed according to Response Evaluation Criteria in Solid tumors (RECIST) to determine progression-free status. Complete response (CR) is disappearance of all lesions (i.e. all evidence of disease, not just the target lesions) determined by 2 observations not less than 4 weeks apart; Partial response (PR) is \> 30% decrease in the sum of longest diameters of target lesions compared to baseline, with response or stable disease observed in non-target lesions, and no new lesions; Stable disease (SD) is neither sufficient shrinkage to qualify for response or sufficient increase to qualify for progressive disease in target lesions, with response or stable disease observed in non-target lesions, and no new lesions; and Progressive disease (PD is: \> 20% increase in the sum of longest diameters of target lesions compared to smallest sum longest diameter recorded. In addition, the sum must also demonstrate an absolute increase of at least 5mm.

Time frame:
6 months
Reported as:
Number · Percentage of participants
Percentage of Participants Progression-free
Percentage of participantsRAD001 Plus Paclitaxel/Carboplatin
Percentage of Participants Progression-free8.2
SecondaryPercentage of Participants With Overall Response Rate (ORR)

ORR was defined as is the proportion of participants with a best overall response of CR or PR. CR is disappearance of all lesions (i.e. all evidence of disease, not just the target lesions) determined by 2 observations not less than 4 weeks apart; Partial response. PR is \> 30% decrease in the sum of longest diameters of target lesions compared to baseline, with response or stable disease observed in non-target lesions, and no new lesions.

Time frame:
3 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Response Rate (ORR)
Percentage of participantsRAD001 Plus Paclitaxel/Carboplatin
Percentage of Participants With Overall Response Rate (ORR)44.9
SecondaryPercentage of Participants With Disease Control Rate (DCR)

DCR was defined as is the percentage of participants with a best overall response of CR or PR or SD. Complete response (CR) is disappearance of all lesions (i.e. all evidence of disease, not just the target lesions) determined by 2 observations not less than 4 weeks apart; Partial response (PR) is \> 30% decrease in the sum of longest diameters of target lesions compared to baseline, with response or stable disease observed in non-target lesions, and no new lesions; Stable disease (SD) is neither sufficient shrinkage to qualify for response or sufficient increase to qualify for progressive disease in target lesions, with response or stable disease observed in non-target lesions, and no new lesions; and Progressive disease (PD is: \> 20% increase in the sum of longest diameters of target lesions compared to smallest sum longest diameter recorded. In addition, the sum must also demonstrate an absolute increase of at least 5mm.

Time frame:
3 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control Rate (DCR)
Percentage of participantsRAD001 Plus Paclitaxel/Carboplatin
Percentage of Participants With Disease Control Rate (DCR)73.5
SecondaryProgression Free Survival (PFS)

PFS was defined as the time from the date of start of treatment to date of event defined as the first documented progression or death due to any cause.

Time frame:
6 months
Reported as:
Median · Days
Progression Free Survival (PFS)
DaysRAD001 Plus Paclitaxel/Carboplatin
Progression Free Survival (PFS)132 (97 to 181)
SecondaryOverall Survival (OS)

OS was defined as the time from date of start of treatment to date of death due to any cause.

Time frame:
12 months
Reported as:
Median · Days
Overall Survival (OS)
DaysRAD001 Plus Paclitaxel/Carboplatin
Overall Survival (OS)298 (207 to 351)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RAD001 Plus Paclitaxel/Carboplatin—28/49 (57.1%)43/49 (87.8%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventRAD001 Plus Paclitaxel/Carboplatin
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders5/49
DYSPNOEARespiratory, thoracic and mediastinal disorders5/49
PNEUMONIAInfections and infestations3/49
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders3/49
PNEUMOTHORAXRespiratory, thoracic and mediastinal disorders3/49
ATRIAL FIBRILLATIONCardiac disorders2/49
ABDOMINAL PAIN UPPERGastrointestinal disorders2/49
CONSTIPATIONGastrointestinal disorders2/49
PAINGeneral disorders2/49
SEPSISInfections and infestations2/49
Most frequent other events
Showing 10 of 41
Most frequent other events
EventRAD001 Plus Paclitaxel/Carboplatin
FATIGUEGeneral disorders17/49
ANAEMIABlood and lymphatic system disorders14/49
NAUSEAGastrointestinal disorders13/49
DYSPNOEARespiratory, thoracic and mediastinal disorders13/49
ALOPECIASkin and subcutaneous tissue disorders12/49
NEUTROPENIABlood and lymphatic system disorders10/49
DIARRHOEAGastrointestinal disorders10/49
DECREASED APPETITEMetabolism and nutrition disorders10/49
CONSTIPATIONGastrointestinal disorders9/49
POLYNEUROPATHYNervous system disorders9/49

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RAD001 Plus Paclitaxel/Carboplatin
Mean62 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)RAD001 Plus Paclitaxel/Carboplatin
Female14
Male35
08

Study locations

9 sites
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Bremen, 28177, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Gauting, 82131, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Hemer, 58675, Germany
  • Novartis Investigative Site
    Koeln, 51109, Germany
  • Novartis Investigative Site
    Leipzig, 04177, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
09

References and documents

Publications

  • Christopoulos P, Engel-Riedel W, Grohe C, Kropf-Sanchen C, von Pawel J, Gutz S, Kollmeier J, Eberhardt W, Ukena D, Baum V, Nimmrich I, Sieder C, Schnabel PA, Serke M, Thomas M. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial. Ann Oncol. 2017 Aug 1;28(8):1898-1902. doi: 10.1093/annonc/mdx268. PubMed 28535181 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2011
First posted
Mar 17, 2011
Start
Apr 2011
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Mar 30, 2016
Last update
Mar 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01317615
Responsible party
Sponsor
First posted
Mar 17, 2011
Start date
Apr 2011
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Mar 30, 2016
Last update
Mar 30, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion